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Peripheral nerve injury causes spontaneous and long-lasting pain, hyperalgesia, and allodynia. Excitatory amino acid receptor-
dependent increases in descending facilitatory drive from the brainstem rostral ventromedial medulla (RVM) contribute to injury-
evoked hypersensitivity. Although increased excitability likely reflects changes in synaptic efficacy, the cellular mechanisms underlying
injury-induced synaptic plasticity are poorly understood. Neuronal pentraxin 1 (NP1), a protein with exclusive CNS expression, is
implicated in synaptogenesis and AMPA receptor recruitment to immature synapses. Its role in the adult brain and in descending pain
facilitation is unknown. Here, we use the spared nerve injury (SNI) model in rodents to examine this issue. We show that SNI increases
RVMNP1 expression and constitutive deletion or silencingNP1 in theRVM, before or after SNI, attenuates allodynia and hyperalgesia in
rats. Selective rescue of RVM NP1 expression restores behavioral hypersensitivity of knock-out mice, demonstrating a key role of RVM
NP1 in the pathogenesis of neuropathic pain.
Introduction
Peripheral nerve injury produces hypersensitivity to both nox-
ious and non-noxious stimuli. Maladaptive plasticity within
brainstem descending pathways linking the rostral ventromedial
medulla (RVM) to the spinal cord is implicated in the pathogen-
esis of neuropathic pain. Persistent pain after injury is linked to
enhanced activation of descending modulatory circuits and in-
creased net descending facilitatory drive, which leads to an am-
plification and spread of pain (Urban and Gebhart, 1999;
Vanegas and Schaible, 2004). Blockade of excitatory amino acid
receptors in the RVM attenuates behavioral hypersensitivity and
the enhanced responsiveness of spinal cord neurons to noxious
and innocuous stimuli, suggesting the involvement of excitatory
amino acid transmission in the descending facilitation of neuro-
pathic pain (Sanoja et al., 2008). Although increased RVM excit-
ability likely reflects altered synaptic efficacy, the mechanisms
underlying injury-induced synaptic plasticity in the pain modu-
latory circuitry remain ill defined.
An early event in excitatory synapse formation is the cluster-
ing of postsynaptic glutamate (Glu) receptors to the synapse
(O’Brien et al., 1997). Targeting and cell surface clustering of
these receptors to the synapse are essential for efficient excitatory
synaptic transmission (O’Brien et al., 1998). Among the mole-
cules hypothesized to act as early mediators of synaptic AMPA
receptor recruitment are the neuronal pentraxins (NPs), proteins
exclusively expressed in the CNS that are homologous to the
C-reactive and acute-phase proteins in the immune system (Tsui
et al., 1996). NP1, a member of the NP family (Xu et al., 2003; Sia
et al., 2007; Hossain, 2008), physically associates with fast excit-
atoryGluR1 andGluR4AMPA receptor subunits in hippocampal
cultures and artificial synapses where it acts trans-synaptically to
cluster AMPA receptors at postsynaptic sites and promote excit-
atory synaptogenesis (O’Brien et al., 1999; Xu et al., 2003; Sia et
al., 2007). Little, however, is known regarding the function of
NP1 in the adult brain in vivo. Given that excitatory amino acid-
dependent increases in descending facilitatory drive from the
RVM are critical for the development of neuropathic pain and
that recombinant NP1 promotes synaptic AMPA receptor clus-
tering, we used the spared nerve injury model (SNI) of neuro-
pathic pain to examine whether NP1 gene deletion or silencing of
NP1 expression in theRVMprotects against allodynia and hyper-
algesia produced by peripheral nerve injury. Our studies reveal
that NP1 is selectively induced in the RVM following SNI and
that gene knockout or the specific silencing of NP1 in the RVM,
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either before or after injury, attenuates SNI-evoked behavioral
hypersensitivity. Furthermore, selective rescue ofNP1 expression
in the RVM restores the allodynia and hyperalgesia that is atten-
uated in NP1 knock-out (KO) mice.
Materials andMethods
Subjects.Male Sprague Dawley rats (Charles River; 300–450 g), NP1 KO
mice (Kirkpatrick et al., 2000), and their wild-type littermates (C57BL/6
background; obtained from heterozygous crossings: F6–8) were main-
tained in temperature- and humidity-controlled facilities accredited by
the American Association for the Accreditation of Laboratory Animal
Care. Food and water were available ad libitum. Experiments were ap-
proved by the NIDA IRP Institutional Care and Use Committee and
conducted in accordancewith The Ethical Guidelines for Investigation of
Experimental Pain in Conscious Animals (International Association for
the Study of Pain) (Zimmermann, 1983).
Lentiviral vectors.The self-inactivatingbicistronic lentiviral transfer vector
constructs pWPI and pLVTHM and the second-generation lentivirus ps-
PAX2 packaging and pMD2G envelope plasmids were obtained from add-
gene (http://www.addgene.org/). The pWPI–NP1 lentiviral vector that
drives NP1 overexpression and the pLVTHM–NP1–short hairpin RNA in-
terference (shRNAi) vector that carries the H1 RNA polymerase III pro-
moter to enable expression of a shRNA for NP1 knockdown were obtained
as previously described (Abad et al., 2006).We used the pLVTHM lentiviral
vector carrying a silencing cassette expressing a shRNAi against no known
target (Random-shRNAi) as a control for the NP1–shRNAi vector. The se-
quence of the NP1–shRNAi vector is as follows: sense, 5-gatccccGTACAG
CCGCCTCAATTCTttcaagagaAGAATTGAGGCGGCTGTACttttt-3; and
antisense, 5-agctaaaaaGTACAGCCGCCTCAATTCTtctcttgaaAGAA
TTGAGGCGGCTGTACggg-3. The sequence in capitals is the NP1
target sequence that corresponds to bases 1004–1022 of NP1 mRNA
(GenBank Accession number U18772). The sequence of the Random-
shRNAi is as follows: sense, 5-gatccccGCAGTGCAATATCGGAAACtt
caagagaGTTTCCGATATTGCACTGCttttt-3; andantisense,5-agctaaaa
aGCAGTGCAATATCGGAAACtctcttgaaGTTTCCGATATTGCACTGC
ggg-3. The efficiency of the NP1-shRNAi silencing cassette to knock down
NP1 expression was tested by immunoblotting in SH-SY5Y cell clones that
permanently overexpress NP1 using actin for normalization.
The viral particles were produced by transient transfection of 293T
cells. High-titer stocks [7 106 transduction units (TU) per microliter]
were obtained by ultracentrifugation and resuspension of the viral pellet
in TNEbuffer (50mMTris-HCl, pH7.5, 130mMNaCl, and 1mMEDTA).
The infectious viral titer was determined by flow cytometry with a FAC-
Scalibur (Beckton-Dickinson)measuring 293T cells expressing GFP 48 h
after transduction with the lentiviral vectors. Viral stocks were stored at
20°C and used within 1 month.
Intra-RVM lentivirus infusions. The RVM is loosely defined as the
midline pontomedullary region including the nucleus raphemagnus and
the adjacent reticular formation (Fields and Heinricher, 1985). Guide
cannulae (C315, Plastics One) were stereotaxically implanted 1mmdor-
sal to the RVM. The coordinates were as follows (in mm): rats: antero-
posterior (AP),10.5 to11.0; lateral (L),0.0; ventral (V),9.7; and
mice: AP, 6.1, L, 0.0; V, 5.0. Animals were single housed after
surgery for the remainder of the study. After recovery from surgery (4–5
d), animals were lightly anesthetized with isoflurane and the microinjec-
tion needle, which extended 1 mm below the guide cannula tip, was
inserted. One microliter of the lentiviral solution (7  106 TU) was
infused over 1 min. The injector was left in place for 4 min to allow for
diffusion. Experiments started 7–10 d after infusion, except for experi-
ments assessing the effects of silencing after SNI, which commenced 3–4
d after infusion. In vitro data showed that the lentivirus vector rapidly
integrates into the cell genome and significantly reduces NP1 protein
levels within 48 h.
Spared nerve injury. The left hindlimb was immobilized under general
anesthesia (rats, Equitesin; mice, ketamine-xylazine), and an incision
made through the biceps femoralismuscle. The sciatic nervewas exposed
and the common peroneal and tibial branches were ligated and tran-
sected, and a 1–2mm section was removed with care to avoid sural nerve
damage (Decosterd and Woolf, 2000; Bourquin et al., 2006). After tran-
section, the muscle fascia and skin were sutured. Subsequent nociceptive
testing (von Frey test and pinprick) was conducted on the sural skin
territory of the plantar surface.
Assessment of nociceptive thresholds.Mechanical thresholds were deter-
mined with the von Frey method (Levin et al., 1978) using 0.6–26.0 g
monofilaments (Stoelting) for rats, and 0.04–6.0 g filaments for mice, as
described previously (Schepers et al., 2008). The up-and-down method
(Chaplan et al., 1994) was used for computation of the 50% response
threshold. For the pinprick test (Tal and Bennett, 1994), a 30 gauge
needle was gently applied to the plantar surface of the hindpaw without
breaking the skin. Nocifensive reactions were measured as the paw lift
duration (in seconds). Testing was conducted by an experimenter
blinded to the treatment condition.
RT-PCR. RVM tissue was dissected and immediately processed for
RNA isolation and DNase I treatment (RNAqueous-Micro Ambion
kit, Applied Biosystems) following manufacturer instructions. For cDNA
synthesis, total RNA was mixed using the Superscript III reverse transcrip-
tase kit (Invitrogen). RT-PCR was performed as duplicate determinations
with specific Taqman probes from the rat Probe Library (Exiqon A/S) de-
signed for primers to rat NP1 (forward, 5-cct tga cct ccc tac acc ag-3;
reverse, 5ctc cgg gtc gat tgt ctt t-3), housekeeping genes Ribosomal
protein S18 (forward, 5-cgagtactcaacaccaacatcg-3; reverse, 5-caccacat
gagcgtatctcc-3), and hydroxymethylbilane synthase (forward, 5 tcc ctg
aag gat gtg cct ac 3; reverse, 5 aca agg gtt ttc ccg ttt g 3). NP1 normal-
ization to both endogenous control genes led to similar results.
Immunohistochemistry. Two or 14 days after SNI, rats were deeply
anesthetizedwith Equitesin (3ml/kg) and transcardially perfusedwith 50
ml of saline solution followed by 150ml of 4% paraformaldehyde. Tissue
was postfixed in paraformaldehyde 4% for 1 h and then stored in 30%
sucrose for 3 d. Forty micrometer sections were collected  RVM: AP
10.04 to11.30mm; Periaqueductal Gray (PAG): AP 4.80 to8.30
mm; spinal cord L4–L6] and processed for immunohistochemistry.Dual
immunostaining of NP1 and tryptophan hydroxylase (TPH) was per-
formed by sequentially incubating sections with NP1 primary antibody
(BD Bioscience; dilution 1:1000) and Alexa Fluor 568 (Invitrogen; dilu-
tion 1:1000) followed by TPHprimary antibody (Santa Cruz Biotechnol-
ogy; dilution 1:500) and Alexa Fluor 488 (Invitrogen; dilution 1:1000).
Dual immunostaining of NP1 and glutamic acid decarboxylase-67
(GAD-67) (primary antibody from Santa Cruz Biotechnology; dilution
1:500) was performed in alternate sections according to the same proto-
col. A total of three sections per animal, representing one of every fifth
section were analyzed. Total number of NP1-positive cells, percentage of
TPH-positive cell expressing NP1, and percentage of GAD-67-positive
cells expressing NP1 were evaluated independently by two observers
blind to the treatment. Single labeling of NP1 was performed in ipsilat-
eral spinal cord and dorsal root ganglia (DRGs) sections, and the number
of cells expressing NP1 was quantified.
Results
Immunohistochemistry revealed low NP1 expression in the spi-
nal cord dorsal horn (SpC), RVM, and PAG of control rats and
undetectable levels in DRGs. SNI induced a sustained increase in
NP1 immunoreactivity in the RVM (Fig. 1a). NP1 immunoreac-
tivity in sham-operated animals was observed in a subset (30–
40%) of GAD67- and TPH-containing neurons (Fig. 1b) and was
primarily restricted to the nuclear compartment. Following SNI,
NP1 was localized to puncta distributed throughout the cyto-
plasm and the number of GABAergic, but not TPH, neurons
expressing NP1 significantly increased (Fig. 1b). This increase
was selective; NP1 expression in DRG, spinal cord, and PAG was
unaltered (Fig. 1a).
We tested whether lentiviral-mediated silencing of NP1 in the
RVM (Fig. 2a–e) affects mechanical hypersensitivity that devel-
ops following SNI. Silencing NP1 before nerve injury attenuated
the development of mechanical allodynia and hyperalgesia (Fig.
2f). Moreover, when silencing was conducted after injury, the
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expression of hypersensitivity was attenuated (Fig. 2g). NP1 si-
lencing did not alter basal nociceptive thresholds in uninjured
animals (Fig. 2g), suggesting the specific involvement of NP1 in
the pathogenesis of persistent pain resulting from nerve injury.
The effects of the silencing vector were attenuated by shifting the
infusion site 1 mm dorsal to the RVM. Mechanical thresholds
(mean SEM) 48 h after infusion of the silencing lentiviral vec-
tor were 8.5 1.9 g (dorsal to target) and 2.5 0.3 g (at target);
baseline thresholds were 11.6 and 10.2 g, respectively. These data
suggest a specific role for NP1 within the RVM in the anti-
allodynic and analgesic effects of NP1 silencing.
Consistent with our studies in rats, SNI-induced mechanical
allodynia was reduced in NP1 knock-out mice (Fig. 2h, left). The
phenotype of knock-out mice was reversed by specifically rescu-
ing NP1 expression in the RVM (Fig. 2h, right).
Discussion
We found increased levels of NP1 in the RVM, but not other pain-
related CNS areas, in a rodent model of chronic neuropathic pain.
This increase appeared to be accompanied by subcellular redistribu-
tion and to occur in GABAergic, but not 5-HT, neurons. Inhibition
ofNP1 expression in the RVM, or deletion of theNP1 gene resulted
in alleviation of nerve injury associated hyperalgesia and allodynia.
Furthermore, restoring NP1 expression selectively in the RVM is
sufficient to reinstate the pain-related behavioral phenotype. To-
gether, these data indicate that peripheral nerve injury induces NP1
in the RVMand that increased expression therein is essential for the
development and expression of nerve injury-evoked pain.
Previous studies have indicated a role for NP1 in pathological
neurodegenerative states, including apoptotic cell death in pri-
Figure 1. SNI selectively induces NP1 in the RVM and induction is restricted to a subset of GABAergic neurons. a, NP1 immunoreactivity is increased in the RVM, but not in the DRG, SpC, or PAG,
2 d after SNI (representative picture and histogram, t5.83, df 10, *p 0.0002, t test). NP1 induction persists for at least 2 weeks after SNI (histogram, t3.83, df 10, *p 0.003,
t test). b, RVM sections obtained 2 d after SNI or sham surgery were stained for NP1 and either TPH or GAD67 (markers of 5-HT and GABAergic cells, respectively). Nerve injury increased the number
of GAD67 cells immunoreactive for NP1 (t 2.67, df 9, *p 0.03, t test), whereas the number of cells coexpressing TPH and NP1 was unaltered.
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mary neuronal cell cultures (DeGregorio-Rocasolano et al., 2001;
Clayton et al., 2012) and hypoxic-ischemic injury in the neonatal
brain (Hossain et al., 2004). The association of NP1 with dystro-
phic neurites surrounding tau deposits and amyloid plaques in
brain samples from Alzheimer patients has also been described
(Abad et al., 2006). Moreover, NP1 has been involved in synap-
togenesis and the clustering of Glu receptors (Xu et al., 2003; Sia
et al., 2007), and in synapse refinement in the developing visual
system (Bjartmar et al., 2006). However, the majority of these
observations derive from in vitro cell culture preparations or
brains in early postnatal developmental stages. Thus, the physio-
logical function for NP1 in vivo and in the adult brain has not
been clearly established (Bjartmar et al., 2006). Our observations
derived from a rodent model of chronic neuropathic pain are
Figure 2. NP1 in the RVM is involved in SNI-evokedmechanical allodynia and hyperalgesia. a, The efficacy of a shRNAi sequence in silencing NP1 expression was confirmed by immunoblotting
in SH-SY5Y neuroblastoma cells constitutively overexpressing NP1. The NP1 shRNAi cassette (or a random shRNAi for control vectors) was then cloned into the lentiviral pLVTHM vector (which
included a reporter GFP cassette) for in vivo transduction. b shows viral-mediated GFP immunostaining within the RVM, indicating successful viral transduction. c, Double immunostaining for GFP
and NP1 demonstrated that expression of NP1 shRNAi (but not random shRNAi) vector resulted in a loss of NP1 immunoreactivity in RVM sections from animals killed 2 d after SNI. d, Quantitative
analysis showed that the silencing vector reduced the number of RVM NP1-immunoreactive neurons at this time point (d; t 2.008; df 9; *p 0.04, one-tailed t test). e, Microinjection of a
lentiviral vector drivingNP1overexpression (pWPI-NP1) increasedRVMNP1mRNA relative to that of the control vector (overexpression effect, F(1,20)22.14,p0.0001, two-wayANOVA).NP1
shRNAi inhibited NP1 mRNA overexpression induced by the pWPI-NP1 vector (silencing effect, F(1,20) 18.02, p 0.0004, overexpression x silencing interaction, F(1,20) 10.39, p 0.004,
two-way ANOVA). A nonsignificant decrease of basal NP1 was observed ( #p 0.05 vs control group; *p 0.05 vs NP1/Random shRNAi group, Bonferroni’s post hoc tests). f, RVM infusion of
NP1-shRNAi 7 d before SNI prevented mechanical allodynia (left, test day effect, F(6,78) 43.9, p 0.001, test day silencing interaction, F(6,78) 9.7, p 0.001, two-way ANOVA) and
attenuated hyperalgesia of the ipsilateral hindpaw (right panel, test day effect, F(6,78) 36.3, p 0.001, test day silencing interaction, F(6,78) 12.7, p 0.001, 2-way ANOVA) relative to
infusionof a control vector (*p0.05 vs RandomshRNAi, Bonferroni’spost hoc tests).g, RVM infusionof the silencing vector 24–48hafter SNI attenuates the expressionof SNI-inducedmechanical
allodynia (left: test day effect, F(4,36) 58.3, p 0.001; test day silencing interaction, F(4,36) 5.2, p 0.002, two-way ANOVA) and hyperalgesia (right: test day effect, F(4,36) 30.1, p
0.001; test day silencing interaction, F(4,36) 12.1, p 0.001, two-way ANOVA). *p 0.05 vs SNI Random shRNAi, Bonferroni’s post hoc tests. No effect of NP1 silencing on basal thresholds is
observed in control (sham-operated) animals.h, Left, NP1 KOmice show attenuated SNI-inducedmechanical allodynia (test day effect, F(4,48) 67.7, p 0.001; test day genotype interaction,
F(4,48) 3.54, p 0.013, two-way ANOVA; *p 0.05 vs WT SNI, Bonferroni’s post hoc tests). Right, Rescuing NP1 expression selectively in the RVM of NP1-deficient mice with a lentiviral vector
driving overexpression of NP1 (NP1) restores the pain phenotype in NP1 KOmice [all groups are NP1 KOmice, they are infusedwith NP1 overexpressing (NP1) or control (CONT) vectors before
sham or SNI surgery; test day effect, F(7,77) 40.6, p 0.001; test day vector interaction, F(7,77) 3.60, p 0.002, two-way ANOVA; p 0.05 vs CONT SNI, Bonferroni’s post hoc tests]. For all
panels, arrows indicate time of infusion. Number of animals per group is shown in parenthesis. Bsln, Baseline measurements. Data represent means SEM.
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consistent with a role for NP1 in functional plasticity in the adult
brain. Specifically, we have identified a role for NP1 in the plastic
processes leading to and maintaining chronic neuropathic pain.
It is worth noting that NP1 immunoreactivity appears confined
to the nuclear compartment under control conditions. This is con-
sistent with the cNLSMapper prediction score of -dependent nu-
clear localization signals in NP1 (http://nls-mapper.iab.keio.ac.jp;
bipartite score: 5.7; sequence:EKGQKDNRPGDKFQLTFPLRTNY-
MYAKVKK)(Kosugi et al., 2009).AlthoughNP1hasbeenpredicted
to be a secreted protein (Kirkpatrick et al., 2000), it has also been
found located in intracellular compartments (Clayton et al., 2012).
Activated NP1 has been shown to distribute in puncta throughout
the cytoplasm and to be associated withmitochondria and involved
inmitochondrial trafficking (Clayton et al., 2012). Interestingly, fol-
lowing nerve injury, NP1 was also seen localized to puncta distrib-
uted throughout the cytoplasm. At present, it is not apparent from
our data whether this subcellular redistribution is necessary for the
pain-facilitating effects of NP1 in our neuropathic pain model.
However, the observation that silencing NP1 expression attenuates
the SNI-inducedhyperalgesia andallodynia indicates that transloca-
tion of existing protein alone is not sufficient and that newly synthe-
sized NP1 is required for these effects.
Interestingly, basal nociception was not altered in NP1 KO
mice. Similarly, inhibition of NP1 expression in the RVM of
sham-operated animals did not change basal pain sensitivity.
This suggests that NP1 is not involved in normal, physiological,
pain transmission. Rather, it seems to be specifically recruited for
and to play a role in pathological pain estates like chronic neu-
ropathy arising from nerve injury. The ability to interfere with
pathological, chronic pain states but not with normal nocicep-
tion has potentially important therapeutic implications.
Consistentwith the literature, allodynia andhyperalgesiawere
fully developed 24–48 h after SNI. Importantly, inhibition of
NP1 48 h after SNI also attenuated nerve injury-evoked allodynia
and hyperalgesia. This observation indicates that NP1 is neces-
sary for the maintenance of neuropathic pain and that blockade
of NP1 expression can reverse the ongoing neuropathy even after
the nerve injury insult has already occurred.
Peripheral nerve injury induces synaptic reorganization and
remodeling of brain circuitry (Navarro et al., 2007). The RVM
integrates information from higher brain areas and descending
projections to the spinal cord dorsal horn modulate the ascend-
ing nociceptive input (Ren and Dubner, 2002). After nerve in-
jury, adaptations within the RVM lead to facilitation of spinal
cord nociceptive output, exacerbation of primary hyperalgesia,
and enhanced sensory input from adjacent regions (i.e., second-
ary hyperalgesia) (Burgess et al., 2002). Furthermore, recent data
indicate that increased descending facilitation from the RVM is
necessary for the development and maintenance of neuropathic
pain (Burgess et al., 2002; Vera-Portocarrero et al., 2006) and is
dependent on glutamatergic transmission (Sanoja et al., 2008).
Our data confirm these studies, establishing a critical role for the
RVM in the maintenance of neuropathic pain, and place NP1 as
one of the elements mediating the long-term changes in RVM
function that sustain chronic neuropathic pain.
Although the precise mechanisms by which NP1 mediates
these effects are unknown, given the established role of NP1 in
synaptic reorganization and AMPA receptor clustering (O’Brien
et al., 1999; Xu et al., 2003; Sia et al., 2007), it is tempting to
hypothesize that NP1 in the RVM facilitates neuropathic pain by
enabling plastic changes within descending pain pathways that
result in mechanical hypersensitivity, a hallmark of neuropathic
pain. Based on the functional responses to noxious stimuli, RVM
cells have been characterized as ON, OFF, or Neutral cells (Fields
and Heinricher, 1985). In chronic pain states, allodynia and hy-
peralgesia are maintained by increased firing of ON cells, de-
creased firing of OFF cells, or both (Heinricher et al., 2009). Both
the ON and OFF cell populations are GABA neurons that project
to the spinal cord, while 5-HT cells are mainly Neutral (Pedersen
et al., 2011). In addition, a population of ON cells includes in-
trinsic GABA interneurons that are able to modulate local activ-
ity. A number of scenarios are consistent with NP1-mediated
increased excitability of GABA cells within the RVM resulting in
SNI-induced allodynia and hyperalgesia. Those include, but are
not limited to, increased activity of ON cells, increased excitabil-
ity of intrinsic GABA neurons resulting in enhanced inhibitory
tone onto OFF cells, or both.
The present study provides new insights as to the role of NP1
in vivo in the adult brain. Furthermore, they suggest that targeting
NP1 may be effective for the treatment of persistent pain.
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